Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Interest Expenses: 2021-2025

Historic Interest Expenses for Oncology Institute (TOI) over the last 5 years, with Q3 2025 value amounting to $1.9 million.

  • Oncology Institute's Interest Expenses fell 1370.79% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 million, marking a year-over-year increase of 2731.89%. This contributed to the annual value of $7.5 million for FY2024, which is 1060.94% up from last year.
  • According to the latest figures from Q3 2025, Oncology Institute's Interest Expenses is $1.9 million, which was down 1370.79% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, Oncology Institute's Interest Expenses peaked at $5.6 million during Q1 2025, and registered a low of $61000.0 during Q2 2022.
  • Over the past 5 years, Oncology Institute's median Interest Expenses value was $1.8 million (recorded in 2023), while the average stood at $1.6 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first surged by 258524.59% in 2023, then crashed by 3982.48% in 2024.
  • Oncology Institute's Interest Expenses (Quarter) stood at $81000.0 in 2021, then dropped by 24.69% to $61000.0 in 2022, then skyrocketed by 3081.97% to $1.9 million in 2023, then plummeted by 39.82% to $1.2 million in 2024, then soared by 64.38% to $1.9 million in 2025.
  • Its Interest Expenses stands at $1.9 million for Q3 2025, versus $1.9 million for Q2 2025 and $5.6 million for Q1 2025.